Search

Search Constraints

You searched for: Author/Creator Garbe, Claus

Search Results

121. PET/CT in malignant melanoma: a two‐tiered healthcare system? Updated healthcare situation regarding initial staging of malignant melanoma with PET/CT. (22nd April 2021)

122. Phenotypic characterization and prognostic impact of circulating γδ and αβ T‐cells in metastatic malignant melanoma. Issue 3 (18th September 2015)

123. Pitfalls in the characterization of circulating and tissue-resident human γδ T cells. Issue 6 (22nd January 2020)

124. Pitfalls in the characterization of circulating and tissue‐resident human γδ T cells. Issue 6 (22nd January 2020)

125. Posterior reversible encephalopathy syndrome in a melanoma patient with dabrafenib and trametinib treatment following immunotherapy. (9th December 2019)

126. Posteriores reversibles Enzephalopathie‐Syndrom bei einem Melanompatienten unter Dabrafenib‐ und Trametinib‐Behandlung nach Immuntherapie. (6th February 2020)

127. Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG "GERMELATOX survey") versus melanoma recurrence to quantify patients' relative values for adjuvant therapy. Issue 46 (November 2016)

128. Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG "GERMELATOX survey") versus melanoma recurrence to quantify patients' relative values for adjuvant therapy. Issue 46 (November 2016)

129. Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study. Issue 5 (13th May 2021)

130. Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage I–III patients. (January 2021)